Story perspectives
Intellia Pauses Trials After Serious Liver Adverse Event
10/27/2025
50 10
1 of 1
Story summary
- Intellia Therapeutics Inc. paused dosing and screening in its Phase 3 MAGNITUDE trials of nexiguran ziclumeran (nex-z) after a serious liver-related adverse event in one participant.
- The pause follows elevated liver transaminases and bilirubin reported on October 24.
- More than 650 patients are enrolled in the trials.
- Intellia's CEO John Leonard emphasized the commitment to patient safety.
- Intellia's shares fell by 43.09% to $14.57.
